• OPEN AN ACCOUNT
Indian Indices
Sensex
84,273.92 208.17
( 0.25%)
Global Indices
Nasdaq
50,149.26 12.58
(0.03%)
Dow Jones
6,984.17 30.87
(0.44%)
Hang Seng
57,678.97 1,315.03
(2.33%)
Nikkei 225
10,354.92 -31.31
(-0.30%)
Forex
USD-INR
90.44 0.11
(0.13%)
EUR-INR
106.84 0.33
(0.31%)
GBP-INR
123.03 0.35
(0.29%)
JPY-INR
0.58 0.00
(-0.07%)

EQUITY - MARKET SCREENER

Strides Pharma Science Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532531
INE939A01011
344.5797109
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
STAR
44.49
8160.05
EPS(TTM)
Face Value()
Div & Yield %
19.9
10
0.45
 

RailTel secures Rs 27-cr order from APCPDCL
Jan 27,2026
The project involves the supply, installation, testing, and configuration of software-defined wide area network (SD-WAN) devices along with associated hardware and licenses at APCPDCL offices. The order includes a five-year warranty and support.

The project is scheduled to be executed by 24 January 2031.

RailTel Corporation, a 'Navratna' PSU, is one of the largest neutral telecom infrastructure providers in the country, owning a Pan-India optical fiber network. As of December 2025, the Government of India held a 72.84% stake in the company.

The company’s standalone net profit jumped 4.72% to Rs 76.07 crore in Q2 FY26, compared with Rs 72.64 crore in Q2 FY25. Revenue from operations rose 12.78% YoY to Rs 951.36 crore in Q2 FY26.

Shares of RailTel Corporation of India rose 0.84% to Rs 330.80 on the BSE.